Covalent HTN Study
Multi-national, randomized, double-blind, parallel group, placebo-controlled study to evaluate the effects of an investigational product on safety and efficacy in subjects with resistant systolic hypertension receiving combination therapy with three or more antihypertensive drugs, including a diuretic
Sponsor: Myogen

CRA: Covalent
Study Drug: Darusentan or LU 135252
Protocol: CV181013
Phase 3
CRO: ICON
Site #:
Investigator #:
CRA:
Central Lab:
IRB:
Subjects / Sites: Subjects per Site
IVRS (Integrated Voice Response System)
Study Design:
IC
35-85
SBP > 140 (or > 130 for DM or CRF)
GFR equal/greater than 30
EC
Secondary HTN
BMI > 43
MI, CVA PTCA, CABG within 6 months
CHF Requiring Rx

2 December 2005
VERSION: 1 2 3 4 5 6 7 8 9

Covalent HTN Study

V1
V2
V3
V4
V5
V6
V7